{"id":35875,"date":"2026-06-30T09:11:00","date_gmt":"2026-06-30T07:11:00","guid":{"rendered":"https:\/\/askme.it\/insights\/ai-territory-segmentation-for-the-pharma-sales-force-the-italian-prescription-data-constraint\/"},"modified":"2026-05-28T17:54:57","modified_gmt":"2026-05-28T15:54:57","slug":"ai-territory-segmentation-for-the-pharma-sales-force-the-italian-prescription-data-constraint","status":"publish","type":"insights","link":"https:\/\/askme.it\/en\/insights\/ai-territory-segmentation-for-the-pharma-sales-force-the-italian-prescription-data-constraint\/","title":{"rendered":"AI territory segmentation for the pharma sales force: the Italian prescription-data constraint"},"content":{"rendered":"
\n

In September 2025 IQVIA launched Field Force Agent, an AI agent dedicated to supporting the pharma sales force, which in its first deployments reported a 27% time savings in HCP visit preparation and follow-up, an 85% satisfaction rate, and a 17% increase in multichannel-equivalent calls. ZS Associates integrated its ZAIDYN platform with Salesforce Agentforce starting in October 2025, with general availability in January 2026, bringing territory intelligence into the operational workflow of the medical sales representative. Trinity Life Sciences reports a $100 million five-year investment in pharma commercial technology, with the monthly visit planning cycle reduced from six weeks to three.<\/p>\n

Farmindustria’s 2025 assembly figures contextualize the Italian market: 71,000 employees in the pharma sector, growing 1.4% year on year and 8% over five years, with production of 56 billion and exports of 54 billion. The 2020 AIFA register counted 29,787 registered medical sales representatives, a figure that remains the most recent public reference. The 2025 ISF Observatory published by Informatori.it and Bhave in June describes a sales force with an average age of around fifty, more than ten years of experience for 69% of the sample, and nine visits per day reached by 50% of representatives. AI segmentation platforms are now grafted onto this fabric, with a promise of optimization that nevertheless requires structural translation to be operational in Italy.<\/p>\n<\/section>\n

\n

From periodic sizing to continuous sensing<\/h2>\n

Pharma territory segmentation has historically been an annual or biennial exercise: response curves, ROI per rep-hour, decisions on network breadth, mapping of target HCPs onto representatives. Next-generation platforms shift the paradigm from periodic sizing to continuous sensing. ZS ZAIDYN Field Performance optimizes territories in real time by detecting coverage gaps, suggesting HCP-rep reassignments based on proximity and relationship history, and integrating with compensation systems to align incentives with new assignments. IQVIA Field Force Agent evaluates thousands of variables \u2014 territory workload, drive time, account value, representative capacity \u2014 to suggest optimal sales force sizing on a horizon that is no longer annual.<\/p>\n

The critical question for the Italian commercial decision-maker in 2026 is not whether these platforms work technically \u2014 they do, and the early deployment numbers prove it \u2014 but on what data they operate. The competitive advantage they claim depends structurally on the quality of single-physician prescription data, which in the United States is available as a commercial product and in Europe does not exist in that form.<\/p>\n<\/section>\n

\n

The data constraint: no Xponent in Europe<\/h2>\n

IQVIA Xponent, the product that tracks prescription volumes per individual HCP covering 93% of the U.S. retail channel, is exclusively available for the United States and Puerto Rico. In Italy, prescription data is the property of the National Health Service and is not commercially redistributed at the single-physician level. Pharma territory segmentation platforms operating in Italy reconstruct territory potential through proxies: aggregated sales data at brick or postal-code level, AIFA open pharma data on reimbursed prescriptions, demographic and epidemiological data, public lists of hospital prescribers. The resulting picture is less precise than the U.S. model but it is what is available, and orthodox sales force sizing methodologies \u2014 Lodish 1988 first and foremost \u2014 have been re-adapted to work on bottom-up proxies rather than top-down prescription response.<\/p>\n

GDPR and the Italian Privacy Code add a second layer of constraint. The Italian Data Protection Authority’s rulings in recent years have clarified that profiling of HCP prescription behavior collected by the medical sales representative requires an explicit legal basis, and in several provisions the Authority has sanctioned companies for profiling carried out under the umbrella of legitimate interest without the consent of the physician concerned. The Farmindustria Code of Conduct of February 21, 2025 confirms the framework: every message that AI segmentation suggests to the representative must be classified as promotional or non-promotional and traceable back, and ACCREDIA certification of scientific information procedures remains annual.<\/p>\n<\/section>\n

\n

CCNL and mobility: AI proposes, HR negotiates<\/h2>\n

The least publicly discussed but operationally most relevant constraint is the Chemical-Pharmaceutical National Collective Labor Agreement (CCNL). A redefinition of a medical sales representative’s territory that implies a change in workplace location or a significant extension of the assigned area requires union negotiation, not the automatic application of an AI optimization. U.S. platforms are designed for organizations in which sales-force mobility is a variable that the system can optimize; in Italy that same mobility is a variable constrained by the contract.<\/p>\n

The practical consequence for 2026 is that the value of AI in Italian territory segmentation manifests less in the macroscopic redesign of territories and more in the micro-optimization of the visit plan within the existing territory. Which HCP to visit first, with what frequency, at what point in the week, with what message: this is the level at which ZAIDYN, Field Force Agent, and Veeva Pre-call Agent produce measurable lift without touching union constraints. Macroscopic redesigns remain triennial exercises planned with HR and union involvement, not continuous operations.<\/p>\n<\/section>\n

\n

What to do now in Italy<\/h2>\n

IQVIA ChannelDynamics in November 2025 confirms for the second consecutive year that Italy is the EU5 country with the highest HCP preference for face-to-face \u2014 45% in 2025, against 25% in the United Kingdom \u2014 and with the highest alignment between channel mix and preferences, at 67%. It is a market in which the unit value of the F2F visit remains higher than in other European markets, and in which AI optimization must preserve this asset rather than erode it. The 17% increase in multichannel-equivalent calls reported by IQVIA Field Force Agent does not mean more F2F visits, it means more useful total engagements \u2014 the rep using the time freed up from manual preparation for higher-quality visits, not for more visits of equal quality.<\/p>\n

For the Italian decision-maker, the 2026 agenda is composed of three operational points. The first is the decision on the data sources that feed segmentation, because in the absence of Xponent the value of the model depends on the quality of available proxies \u2014 AIFA open data, ISTAT demographic data, public prescriber registers, brick-level sales data. The second is the process design with HR and labor relations, because the promise of dynamic territory requires a preliminary conversation that most companies postpone. The third is verification of HCP consent for profiling: legitimate interest is not enough. Only after these three steps does the choice between ZAIDYN, Field Force Agent, and the territory-design modules integrated in Vault CRM or Agentforce Life Sciences become relevant.<\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

IQVIA Field Force Agent reports 27% time savings and 85% user satisfaction in 2025 early deployments. ZS ZAIDYN integrated with Salesforce Agentforce in January 2026. But Europe has no equivalent of the U.S. IQVIA Xponent: pharma territory segmentation in Italy must be built on different proxies and within union constraints on workplace mobility.<\/p>\n","protected":false},"featured_media":35877,"menu_order":0,"template":"","insights_category":[968],"insights_tags":[911,971,909,975,910],"class_list":["post-35875","insights","type-insights","status-publish","has-post-thumbnail","hentry","insights_category-ai-and-pharma","insights_tags-iqvia-xponent","insights_tags-medical-representatives","insights_tags-sales-force-sizing","insights_tags-territory-segmentation","insights_tags-zs-zaidyn"],"acf":[],"_links":{"self":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights\/35875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights"}],"about":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/types\/insights"}],"version-history":[{"count":1,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights\/35875\/revisions"}],"predecessor-version":[{"id":35876,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights\/35875\/revisions\/35876"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/media\/35877"}],"wp:attachment":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/media?parent=35875"}],"wp:term":[{"taxonomy":"insights_category","embeddable":true,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights_category?post=35875"},{"taxonomy":"insights_tags","embeddable":true,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights_tags?post=35875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}